Ropes & Gray represented Accent Therapeutics in an asset purchase agreement with Boehringer Ingelheim for a preclinical potentially first-in-class small molecule oncology program for treating tumors with high interferon-stimulated gene expression. The deal was announced on October 8 and financial terms were not disclosed.
The Ropes & Gray team was led by life sciences partner Hannah England and life sciences associate James Gould and included tax partner David Saltzman.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.